News

Publix Food Recall Update as 'Foreign Material' Found in Multiple Products
Publix has had to manage several recalls involving both meat and non-meat products since the start of the year.
US FDA approves KalVista Pharma's swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Food Dyes Are Lurking in Surprising Places
In addition to finding these dyes in brightly colored processed foods, the researchers also found them in more muted foods ...
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
American Kratom Association Applauds FDA Crackdown on Dangerous Chemically Manipulated 7-OH, Pseudoindoxyl and 'M' Products
Synthetic products posing as kratom mislead and endanger consumers; AKA urges FDA to take decisive action against violative ...
A Promising New AIDS Drug Highlights The Dangers Of Price Controls
The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...
STAT4h
Inside the staff exodus and tanking morale that threaten Makary’s FDA
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
Grist on MSN5h
How to access food before, during, and after a disaster
Store items in a cool, dry place away from direct sunlight. Place your food supply on high shelves to keep them far from any ...
Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment
Mustang Bio shares more than quadrupled, to $5.23, after the company on Monday said the Food and Drug Administration granted orphan drug designation to Mustang for MB-101 for the treatment of ...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable ...
US FDA approves KalVista Pharma's swelling disorder drug
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.